Both therapies produce better outcomes, better dosing accuracy, and better safety profiles when administered in a clinical setting rather than self-managed with online peptides
Patients with Chronic Pulmonary Disease: Oxycodone and acetaminophen tablets-treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with a substantially decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression are at increased risk of decreased respiratory drive including apnea, even at recommended dosages of oxycodone and acetaminophen Tablets [see WARNINGS
doi: 10.1053/j.gastro.2013.07.011 40 IshikawaTYoshidaNTokudaHKokuraSNakabeNKuchideMet al
Weschawalit, S., Thongthip, S., Phutrakool, P., & Asawanonda, P
Cancer Manag Res (2019) 11:323751
10.1002/jsfa.6936 14 BertschC.Ramirez-SueroM.Magnin-RobertM.LarignonP.ChongJ.Abou-MansourE.et al